产品
服务
公司
洞察
Hanpars 在 2025 年发布的有关医药市场、采购和法规的文章。文章保留原始日期，仅作背景参考，不构成当前建议。
20 篇存档文章
China's API sector grows with focus on sustainability, complex molecules, and regulatory alignment...
China's FDF sector evolves rapidly with a shift toward high-value, complex formulations amid steady market growth and policy support...
Profiling top Chinese API producers like Zhejiang Huahai, CSPC Pharma, and their cutting-edge advancements...
Chinese FDF manufacturers are expanding exports, gaining global share through quality improvements and partnerships...
Chinese APIs power 30-40% of global generics, with exports rising amid quality improvements...
Chinese firms are driving FDF innovation in biosimilars, complex generics, and novel deliveries...
NMPA reforms align China's API industry with global standards, boosting quality and exports...
Chinese API makers adopt green chemistry and waste reduction amid environmental pressures...
As we look toward 2030, China's Active Pharmaceutical Ingredient (API) industry stands at an inflection point, with transformative forces reshaping its trajecto…
The global Active Pharmaceutical Ingredient (API) landscape is characterized by a complex interplay of cooperation and competition, with China occupying a centr…
China's Active Pharmaceutical Ingredient (API) industry is experiencing a profound digital transformation, with artificial intelligence (AI) and advanced analyt…
China's Active Pharmaceutical Ingredient (API) industry is undergoing a significant transformation toward sustainability, with green chemistry initiatives gaini…
China's biopharmaceutical sector is undergoing a remarkable transformation, with rapid advances in biological Active Pharmaceutical Ingredients (APIs) positioni…
China's evolving disease burden is creating a powerful domestic driver for pharmaceutical innovation, particularly in the Active Pharmaceutical Ingredients (API…
The pharmaceutical industry is approaching a significant patent cliff, with blockbuster drugs worth over $1.92 billion facing patent expiration between 2024 and…
China's dominance in global pharmaceutical supply chains has reached unprecedented levels, creating both opportunities and challenges for the global healthcare …
The Chinese API manufacturing sector is experiencing an unprecedented wave of capital investment, fundamentally transforming the industry's capabilities and glo…
The landscape of China's Active Pharmaceutical Ingredient (API) industry is undergoing a profound transformation. Once primarily known as the world's factory fo…
China's regulatory framework for Active Pharmaceutical Ingredients (APIs) has undergone a profound transformation in recent years, culminating in comprehensive …
China's Active Pharmaceutical Ingredient (API) market stands as a cornerstone of drug manufacturing worldwide. As we navigate through 2025, this critical sector…
请提供分子或原料名称、质量标准和目的地。德黑兰团队会回复需要确认的问题、所需文件以及下一步安排。
